Study of ZIO-101 in Multiple Myeloma

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziopharm

Criteria

Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.